Market Cap
$194.3M
ORMP
ORAMED PHARMACEUTICALS INC.
$4.49 ▲ +0.22%
Prev close $4.48Market cap$194.3M
12-mo target$7.00 (+55.9%)
Insider Selling Cluster (2 insiders)13 New Institutional Positions8 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ORMP right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Inst. Holders
50 funds
Inst. Value
$43.2M
Inst. Activity
13 buys / 8 sells
Insider Activity
$0.00 buy / $1.2M sell
Insider Net $
-$1.2M
SEC Reports
2
Price chart 30d -8.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 Insider
Gabay Avraham sold 20,000 shares
Chief Financial Officer @ $4.51 ($90.2K)
Oct 1, 2026 Insider
Hexter Joshua sold 30,000 shares
COO & CBO @ $4.51 ($135.3K)
Sep 24, 2026 Insider
Gabay Avraham was granted 209,291 shares
Chief Financial Officer
Aug 14, 2026 short_interest_report
Jul 2, 2026 SEC Short Interest: ORMP up 23% to 1.0M shares
Settlement 2026-08-14 | Days to cover: 5.85 | ≈2.47% of shares outstanding (est.)
COO/CBO Joshua Hexter and CFO Avraham Gabay collectively sold $942K in open-market shares on July 1, 2026, representing
CLUSTER — Impact 4/10
Oramed Pharmaceuticals extended payment obligations from Scilex Holding Company, covering approximately $29.5M Tranche A
8-K — Impact 5/10
Jun 30, 2026 Inst.
MERCER GLOBAL ADVISORS INC — ADD
3,810,540 shares ($18.3M)
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
1,608,111 shares ($7.7M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 9, 2024 | HC Wainwright & Co. | REITERATE | Neutral | 43% |
| May 20, 2024 | HC Wainwright & Co. | REITERATE | Neutral | 43% |
| May 17, 2023 | Canaccord Genuity | MAINTAIN | Hold | 47% |
| Jan 17, 2023 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
| Jan 12, 2023 | Canaccord Genuity | DOWNGRADE | Hold | 47% |
| May 16, 2022 | Aegis Capital | MAINTAIN | Buy | — |
| Feb 18, 2022 | Cantor Fitzgerald | INITIATE | Overweight | 49% |
| Nov 30, 2021 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Nov 29, 2021 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Nov 2, 2021 | Aegis Capital | MAINTAIN | Buy | — |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| May 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Apr 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% |
Price targets
Where 1 covering analysts think ORMP trades over the next 12 months.
$7.00 +55.9% upside Strong Buy
Current$4.49 Low$7.00 Median$7.00 High$7.00 1 analysts
$7.00$7.00
Analyst rating None as of Oct 3, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
2 SEC filing reports analyzed · 0 bullish, 0 bearish, 1 mixed, 1 neutral · avg impact 4.5/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 14, 2026
short_interest_report
Short Interest: ORMP up 23% to 1.0M shares
Settlement 2026-08-14 | Days to cover: 5.85 | ≈2.47% of shares outstanding (est.)
Aug 12, 2026
earnings_calendar
ORMP Q2 2026 Earnings Scheduled — 2026-08-12
Mar 25, 2026
earnings_calendar
ORMP Q4 2025 Earnings After Market Close — 2026-03-25
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.43 | $0.43–$0.43 | -62.0% | -17.3% | — | $0.0B | 1 |
| Next Q | $0.37 | $0.37–$0.37 | 48.0% | -19.6% | — | $0.0B | 1 |
| Current FY | $4.47 | $4.47–$4.47 | 198.0% | +93.5% | 0↑ 1↓ | $0.0B | 1 |
| Next FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.430 | — |
| 7d ago | $0.520 | -0.090 |
| 30d ago | $0.520 | -0.090 |
| 60d ago | $0.520 | -0.090 |
| 90d ago | $0.000 | +0.430 |
Institutional ownership
Which big funds own ORMP (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $43.2M total value (8,991,398 shares) as of 2026-Q2. Top holders: MERCER, BlackRock,, GEODE. Net buying activity: 13 institutions added/increased vs 8 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| MERCER GLOBAL ADVISORS INC /ADV | 3,810,540 | $18.3M | 42.4% | ADD +99.4% |
| BlackRock, Inc. | 1,608,111 | $7.7M | 17.9% | DOUBLED +1644.3% |
| GEODE CAPITAL MANAGEMENT, LLC | 500,690 | $2.4M | 5.6% | DOUBLED +1962.0% |
| GOLDMAN SACHS GROUP INC | 253,293 | $1.2M | 2.8% | — |
| STATE STREET CORP | 242,100 | $1.2M | 2.7% | — |
| Rathbones Group PLC | 233,018 | $1.1M | 2.6% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 229,882 | $1.1M | 2.6% | — |
| DIMENSIONAL FUND ADVISORS LP | 202,609 | $973.8K | 2.3% | ADD +28.1% |
| NORTHERN TRUST CORP | 184,920 | $889.5K | 2.1% | — |
| RENAISSANCE TECHNOLOGIES LLC | 183,800 | $884.1K | 2.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MERCER GLOBAL ADVISORS INC /ADV | ADD | 1,910,540 | 3,810,540 | +99.4% | $18.3M |
| BlackRock, Inc. | DOUBLED | 92,192 | 1,608,111 | +1644.3% | $7.7M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 24,282 | 500,690 | +1962.0% | $2.4M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 158,209 | 202,609 | +28.1% | $973.8K |
| JANE STREET GROUP, LLC | DOUBLED | 52,540 | 113,349 | +115.7% | $545.2K |
| MARSHALL WACE, LLP | TRIM | 259,611 | 101,953 | -60.7% | $490.4K |
| UBS Group AG | DOUBLED | 11,667 | 67,671 | +480.0% | $325.5K |
| AMERICAN CENTURY COMPANIES INC | ADD | 32,307 | 59,775 | +85.0% | $287.5K |
| MORGAN STANLEY | DOUBLED | 14,052 | 43,357 | +208.5% | $208.5K |
| CITADEL ADVISORS LLC | TRIM | 98,629 | 41,565 | -57.9% | $199.9K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
4 insiders, 32 transactions. Net -$1.2M — $0.00 bought, $1.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Gabay Avraham | Chief Financial Officer | SELL | 20,000 | $4.51 | $90.2K |
| Oct 1, 2026 | Hexter Joshua | COO & CBO | SELL | 30,000 | $4.51 | $135.3K |
| Sep 24, 2026 | Gabay Avraham | Chief Financial Officer | AWARD | 209,291 | — | — |
| Sep 24, 2026 | Hexter Joshua | COO & CBO | AWARD | 75,455 | — | — |
| Sep 24, 2026 | Hexter Joshua | COO & CBO | AWARD | 209,291 | — | — |
| Sep 24, 2026 | Hexter Joshua | COO & CBO | D | 50,000 | — | — |
| Sep 24, 2026 | Hexter Joshua | COO & CBO | D | 36,000 | — | — |
| Sep 24, 2026 | Kidron Miriam | Chief Scientific Officer | AWARD | 209,291 | — | — |
| Sep 24, 2026 | KIDRON NADAV | President and CEO | D | 196,500 | — | — |
| Sep 24, 2026 | Kidron Miriam | Chief Scientific Officer | D | 47,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ORMP.
Shares short
1,307,745
Settlement Sep 15, 2026
Change vs prior
+13.3%
Semi-monthly cycle
Days to cover
7.4
At avg daily volume
Of shares outstanding
≈3.1%
Estimate — not % of float
All ORMP filing & press-release reports (2)
- CLUSTER reportJul 2, 2026
- 8-K reportJun 30, 2026